{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["104(4)"],"submitter":["Halpern AB"],"funding":["NHLBI NIH HHS","NCI NIH HHS"],"journal":["Haematologica"],"pagination":["e143-e146"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6442971"],"repository":["biostudies-literature"],"pubmed_title":["Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms."],"pmcid":["PMC6442971"],"funding_grant_id":["T32 HL007093","T32 CA009515"],"pubmed_authors":["Othus M","Orlowski KF","Oehler VG","Scott BL","Gardner KM","Orozco JJ","Hendrie PC","Chen TL","Percival MM","Becker PS","Huebner EM","Anwar A","Cassaday RD","Walter RB","Halpern AB","Smith HA","Buckley SA","Estey EH"],"additional_accession":[]},"is_claimable":false,"name":"Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.","description":null,"dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Apr","modification":"2026-05-03T19:03:20.645Z","creation":"2025-04-06T15:45:17.279Z"},"accession":"S-EPMC6442971","cross_references":{"pubmed":["30409798"],"doi":["10.3324/haematol.2018.204792"]}}